Accreditation/
Credit Designation
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co.
Oncology Best Practice™: The Latest Advances on PARP Inhibition in Ovarian Cancer: What You Need to Know
.jpg)
Oncology Best Practice™: The Latest Advances on PARP Inhibition in Ovarian Cancer: What You Need to Know
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at [email protected] or call (609) 325-4668
Overview
Oncology Best Practices™ is a series of interactive meetings hosted by leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. These meetings will be led by a nationally renowned expert in ovarian cancer. The live session begins with a brief update that will review current guidelines, best practices and new data in ovarian cancer. The case discussions that follow will explore common clinical challenges encountered in the community setting for treating patients with PARP inhibitors in the treatment and maintenance settings as well as implementing personalized therapies, combination strategies and management of associated adverse events.
Benefits of Attending
- Interact with a nationally recognized ovarian cancer expert and local peers at each meeting
- Explore the application of clinical data and expert guidelines to common challenging patient scenarios
- Develop strategies for managing adverse events association with PARP inhibition for your patients
- Learn about ongoing clinical trial opportunities for your patients with ovarian cancer
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co.
Target Audience
This activity is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Pathologists, fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess timing and selection of molecular testing methods for patients with ovarian cancer based on current evidence and treatment guidelines
- Review key findings from clinical trials that have evaluated PARP inhibitors for patients with ovarian cancer in the treatment and maintenance settings
- Examine strategies that are being explored to personalize PARP inhibitor use for patients with ovarian cancer including combination strategies
- Utilize effective measures to manage and mitigate adverse events associated with PARP inhibitor use
Program Chair
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
